Date: 11/29/2021
Your Name:Allen Cole Burks
Manuscript Title: Feasibility of a Prototype Carbon Nanotube Enabled Stationary Digital Chest Tomosynthesis System
for Identification of Pulmonary Nodules by Pulmonologists
Manuscript number (if known): JTD-21-1381-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	University of North Carolina at Chapel Hill, University Cancer Research Fund	Lineberger Comprehensive Clinical Cancer Center study number LCCC1337
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone	
3	Royalties or licenses	xNone	

4	Consulting fees	x None	
7	consuming rees		
5	Payment or honoraria for	x None	
5	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	x None	
	testimony		
	•		
7	Support for attending meetings and/or travel	xNone	
	meetings and of traver		
8	Patents planned, issued or	xNone	
	pending		
9	Participation on a Data	xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	xNone	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	Nava	
11	Stock or stock options	xNone	
12	Receipt of equipment,	x None	
14	materials, drugs, medical	^NONC	
	writing, gifts or other		
	services		
13	Other financial or non-	xNone	
	financial interests		

The current study was partially funded by the institutional University Cancer Research Fund via a Lineberger Comprehensive Clinical Cancer Center award.
I have no conflicts of interest to disclose regarding the current manuscript.

Please place an "X" next to the following statement to indicate your agreement:		
x_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	11/29/2021
Your Na	me:Jason Akulian
Manusc	ript Title: Feasibility of a Prototype Carbon Nanotube Enabled Stationary Digital Chest Tomosynthesis System
for Iden	tification of Pulmonary Nodules by Pulmonologists
Manusc	ript number (if known): JTD-21-1381-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	University of North Carolina at Chapel Hill, University Cancer Research Fund	Lineberger Comprehensive Clinical Cancer Center study number LCCC1337
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone	
3	Royalties or licenses	xNone	

4	Consulting fees	_xNone	
5	Payment or honoraria for	xNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	x None	
O	testimony	xivone	
	,		
7	Support for attending meetings and/or travel	xNone	
8	Patents planned, issued or	xNone	
	pending		
0	5 5 .	A1	
9	Participation on a Data Safety Monitoring Board or	xNone	
	Advisory Board		
10	Leadership or fiduciary role	x None	
10	in other board, society,	XNOTIC	
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	x None	
12	Receipt of equipment,	xNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	xNone	
	financial interests		

1	vas partially funded by the institu nical Cancer Center award.	itional University Cancer Resear	ch Fund via a Lineberger
I have nothing to di	sclose regarding the current man	nuscript.	

Please place an "X" next to the following statement to indicate your agreement:		
_x I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date: 11/29/2021
Your Name:Christina R. MacRosty
Manuscript Title: Feasibility of a Prototype Carbon Nanotube Enabled Stationary Digital Chest Tomosynthesis System
for Identification of Pulmonary Nodules by Pulmonologists
Manuscript number (if known): JTD-21-1381-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	University of North Carolina at Chapel Hill, University Cancer Research Fund	Lineberger Comprehensive Clinical Cancer Center study number LCCC1337
	Time frame: past 36 months		36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone	
3	Royalties or licenses	xNone	

4	Consulting fees	x None	
7	consuming rees		
5	Payment or honoraria for	x None	
5	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	x None	
	testimony		
	•		
7	Support for attending meetings and/or travel	xNone	
	meetings and of traver		
8	Patents planned, issued or	xNone	
	pending		
9	Participation on a Data	xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	xNone	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	Nava	
11	Stock or stock options	xNone	
12	Receipt of equipment,	x None	
14	materials, drugs, medical	^NONC	
	writing, gifts or other		
	services		
13	Other financial or non-	xNone	
	financial interests		

The current study was partially funded by the institutional University Cancer Research Fund via a Lineberger Comprehensive Clinical Cancer Center award.
I have no conflicts of interest to disclose regarding the current manuscript.

Please place an "X" next to the following statement to indicate your agreement:		
_x I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	11/29/2021
Your Na	me:Sohini Ghosh
Manusc	ript Title:_ Feasibility of a Prototype Carbon Nanotube Enabled Stationary Digital Chest Tomosynthesis System
for Iden	tification of Pulmonary Nodules by Pulmonologists
Manusc	ript number (if known): JTD-21-1381-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	University of North Carolina at Chapel Hill, University Cancer Research Fund	Lineberger Comprehensive Clinical Cancer Center study number LCCC1337
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone	
3	Royalties or licenses	xNone	

4	Consulting fees	x None	
7	consuming rees		
5	Payment or honoraria for	x None	
5	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	x None	
	testimony		
	•		
7	Support for attending meetings and/or travel	xNone	
	meetings and of traver		
8	Patents planned, issued or	xNone	
	pending		
9	Participation on a Data	xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	xNone	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	Nava	
11	Stock or stock options	xNone	
12	Receipt of equipment,	x None	
14	materials, drugs, medical	^NONC	
	writing, gifts or other		
	services		
13	Other financial or non-	xNone	
	financial interests		

The current study was partially funded by the institutional University Cancer Research Fund via a Lineberger Comprehensive Clinical Cancer Center award.
I have no conflicts of interest to disclose regarding the current manuscript.

Please place an "X" next to the following statement to indicate your agreement:		
_x I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	11/29/2021
Your Na	ame: Adam Belanger
Manus	cript Title:_ Feasibility of a Prototype Carbon Nanotube Enabled Stationary Digital Chest Tomosynthesis System
for Ider	ntification of Pulmonary Nodules by Pulmonologists
Manus	cript number (if known): JTD-21-1381-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	University of North Carolina at Chapel Hill, University Cancer Research Fund	Lineberger Comprehensive Clinical Cancer Center study number LCCC1337
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone	
3	Royalties or licenses	xNone	

4	Consulting fees	x None	
7	consuming rees		
5	Payment or honoraria for	x None	
5	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	x None	
	testimony		
	•		
7	Support for attending meetings and/or travel	xNone	
	meetings and of traver		
8	Patents planned, issued or	xNone	
	pending		
9	Participation on a Data	xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	xNone	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	Nava	
11	Stock or stock options	xNone	
12	Receipt of equipment,	x None	
14	materials, drugs, medical	^NONC	
	writing, gifts or other		
	services		
13	Other financial or non-	xNone	
	financial interests		

The current study was partially funded by the institutional University Cancer Research Fund via a Lineberger Comprehensive Clinical Cancer Center award.
I have no conflicts of interest to disclose regarding the current manuscript.

Please place an "X" next to the following statement to indicate your agreement:		
_x I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:11	1/29/2021
<b>Your Name</b>	e:Muthu Sakthivel
Manuscript	t Title: Feasibility of a Prototype Carbon Nanotube Enabled Stationary Digital Chest Tomosynthesis System
for Identific	cation of Pulmonary Nodules by Pulmonologists
Manuscript	t number (if known): JTD-21-1381-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initial	planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	University of North Carolina at Chapel Hill, University Cancer Research Fund	Lineberger Comprehensive Clinical Cancer Center study number LCCC1337	
	Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone		
3	Royalties or licenses	xNone		

4	Consulting fees	x None	
7	consuming rees		
5	Payment or honoraria for	x None	
5	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	x None	
	testimony		
	•		
7	Support for attending meetings and/or travel	xNone	
	meetings and of traver		
8	Patents planned, issued or	xNone	
	pending		
9	Participation on a Data	xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	xNone	
	committee or advocacy		
11	group, paid or unpaid	Nava	
11	Stock or stock options	xNone	
12	Receipt of equipment,	x None	
14	materials, drugs, medical	^NONC	
	writing, gifts or other		
	services		
13	Other financial or non-	xNone	
	financial interests		

The current study was partially funded by the institutional University Cancer Research Fund via a Lineberger Comprehensive Clinical Cancer Center award.
I have no conflicts of interest to disclose regarding the current manuscript.

Please place an "X" next to the following statement to indicate your agreement:		
_x I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date: 11/29/2021
Your Name:Thad S. Benefield
Manuscript Title: Feasibility of a Prototype Carbon Nanotube Enabled Stationary Digital Chest Tomosynthesis System
for Identification of Pulmonary Nodules by Pulmonologists
Manuscript number (if known): JTD-21-1381-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	University of North Carolina at Chapel Hill, University Cancer Research Fund	Lineberger Comprehensive Clinical Cancer Center study number LCCC1337
	Time frame: past 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone	
3	Royalties or licenses	xNone	

4	Consulting fees	_xNone	
5	Payment or honoraria for lectures, presentations,	xNone	
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	x None	
•	testimony		
	•		
7	Support for attending meetings and/or travel	xNone	
8	Patents planned, issued or	xNone	
	pending		
9	Participation on a Data	xNone	
	Safety Monitoring Board or		
10	Advisory Board  Leadership or fiduciary role	x None	
10	in other board, society,	xNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	xNone	
12	Receipt of equipment, materials, drugs, medical	xNone	
	writing, gifts or other services		
13	Other financial or non-	xNone	
	financial interests		

The current study was partially funded by the institutional University Cancer Research Fund via a Lineberger Comprehensive Clinical Cancer Center award.
I have no conflicts of interest to disclose.

Please place an "X" next to the following statement to indicate your agreement:		
_x I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:_	11/29/2021
Your N	ame:Christina R. Inscoe
Manus	cript Title:_ <u>Feasibility of a Prototype Carbon Nanotube Enabled Stationary Digital Chest Tomosynthesis System</u>
for Ide	ntification of Pulmonary Nodules by Pulmonologists
Manus	cript number (if known): JTD-21-1381-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	University of North Carolina at Chapel Hill, University Cancer Research Fund	Lineberger Comprehensive Clinical Cancer Center study number LCCC1337
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone	
3	Royalties or licenses	YXintek	Royalty payment from University involvement in related IP

4	Consulting fees	_xNone	
5	Payment or honoraria for	x_None	
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	xNone	
	testimony		
7	Support for attending	xNone	
	meetings and/or travel		
_			
8	Patents planned, issued or	Y_ Patent issued	Co-inventor of IP for stationary chest tomosynthesis
	pending		
9	Participation on a Data	x None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	xNone	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	N.	
11	Stock or stock options	xNone	
12	Receipt of equipment,	x None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	x_None	
	financial interests		

The current study was partially funded by the institutional University Cancer Research Fund via a Lineberger Comprehensive Clinical Cancer Center award.

I am co-inventor of University IP for stationary chest tomosynthesis which has been licensed to Xintek. Small royalty payments have been received due to this relationship.

Please place an "X" next to the following statement to indicate your agreement:
_x I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 11/29/2021
Your Name: Otto Zhou
Manuscript Title: Feasibility of a Prototype Carbon Nanotube Enabled Stationary Digital Chest Tomosynthesis System
for Identification of Pulmonary Nodules by Pulmonologists
Manuscript number (if known): ITD-21-1381-CI

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	University of North Carolina at Chapel Hill, University Cancer Research Fund	Lineberger Comprehensive Clinical Cancer Center study number LCCC1337
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone	
3	Royalties or licenses	Xintek, Inc	Board director of Xintek, to which technology is licensed.

4	Consulting fees	_xNone	
5	Payment or honoraria for lectures, presentations, speakers bureaus,	xNone	
	manuscript writing or		
	educational events		
6	Payment for expert testimony	xNone	
_			
7	Support for attending meetings and/or travel	xNone	
8	Patents planned, issued or	_ Issued patents related to	Co-Inventor of the CNT x-ray source array and stationary
	pending	tomosynthesis	tomosynthesis technologies
9	Participation on a Data	x None	
9	Safety Monitoring Board or	xNone	
	Advisory Board		
10	Leadership or fiduciary role	xNone	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options		Hold stocks and stock antions in Vintal
11	Stock of Stock options		Hold stocks and stock options in Xintek
12	Receipt of equipment,	xNone	
	materials, drugs, medical		
	writing, gifts or other		
12	Services	Nana	
13	Other financial or non- financial interests	xNone	
	inialiciai inicerests		

The current study was partially funded by the institutional University Cancer Research Fund via a Lineberger Comprehensive Clinical Cancer Center award.

I am Co-inventor of the CNT x-ray source array and stationary digital tomosynthesis technologies, and co-founder and board director of the company to which the technology is licensed. I hold stocks and shares in the Xintek Inc company.

Please place an "X" next to the following statement to indicate your agreement:
_x I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: <u>11/29/2021</u>
Your Name: Jianping Lu
Manuscript Title: Feasibility of a Prototype Carbon Nanotube Enabled Stationary Digital Chest Tomosynthesis System
for Identification of Pulmonary Nodules by Pulmonologists
Manuscript number (if known): ITD-21-1381-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	University of North Carolina at Chapel Hill, University Cancer Research Fund	Lineberger Comprehensive Clinical Cancer Center study number LCCC1337
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone	
3	Royalties or licenses	Xintek, Inc	Small equity shares of Xintek, to which technology is licensed.

4	Consulting fees	Xintek Inc	Consultant
		Surround Medical Systems	Consultant
5	Payment or honoraria for	xNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	x None	
0	testimony	xNone	
	testimony		
7	Support for attending	x None	
-	meetings and/or travel		
	,		
8	Patents planned, issued or	None	Co-Inventor of the digital chest tomosynthesis system
	pending		
9	Participation on a Data	xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	xNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	x None	
	Static of Static Options		
12	Receipt of equipment,	xNone	
	materials, drugs, medical	_	
	writing, gifts or other		
	services		
13	Other financial or non-	x_None	
	financial interests		

The current study was partially funded by the institutional University Cancer Research Fund via a Lineberger Comprehensive Clinical Cancer Center award.

I am Co-inventor of the stationary digital chest tomosynthesis system and shareholder of the company (Xintek Inc) to which the technology is licensed. I receive consultant fees from Xintek and Surround Medical Systems.

Please place an "X" next to the following statement to indicate your agreement:
_x I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:	11/29/2021
Your Na	me: Yueh Z. Lee
Manusc	ript Title: Feasibility of a Prototype Carbon Nanotube Enabled Stationary Digital Chest Tomosynthesis System
for Iden	tification of Pulmonary Nodules by Pulmonologists
Manusc	rint number (if known): ITD-21-1381-CI

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)			
		Time frame: Since the initial	planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	University of North Carolina at Chapel Hill, University Cancer Research Fund	Lineberger Comprehensive Clinical Cancer Center study number LCCC1337			
	Time frame: past 36 months					
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone				
3	Royalties or licenses	X None				

A Consulting fees    X_None				
lectures, presentations, speakers bureaus, manuscript writing or educational events  6 Payment for expert testimony  7 Support for attending meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-	4	Consulting fees	_xNone	
lectures, presentations, speakers bureaus, manuscript writing or educational events  6 Payment for expert testimony  7 Support for attending meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-				
lectures, presentations, speakers bureaus, manuscript writing or educational events  6 Payment for expert testimony  7 Support for attending meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-				
speakers bureaus, manuscript writing or educational events  6	5	lectures, presentations,	xNone	
manuscript writing or educational events Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Patents planned, issued or pending  None  Co-Inventor of the digital chest tomosynthesis system  Z None  X None  X None  X None  X None  X None  Table Translation or none  X None				
educational events  Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  To Other financial or non-    X_None				
6 Payment for expert testimony  7 Support for attending meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-    X_None				
testimony  Support for attending meetings and/or travel  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  None  Co-Inventor of the digital chest tomosynthesis system  Lax_None  x_None  x_None  x_None  x_None  x_None  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-  x_None	6		x None	
Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Receipt of equipment, materials, drugs, medical writing, gifts or other services  None  ——None		•		
Mone   Co-Inventor of the digital chest tomosynthesis system		,		
pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  X None  x None  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-  x None	7		xNone	
pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  X None  x None  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-  x None				
pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  X None  x None  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-  x None				
9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-    X_None	8	-	None	Co-Inventor of the digital chest tomosynthesis system
Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-    X_None				
Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-    X_None	0	Dankisia skiana sa a Data	Nava	
Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options   x_None	9	Safety Monitoring Board or	xnone	
10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-				
in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options xNone  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or nonxNone	10	•	x None	
committee or advocacy group, paid or unpaid  11 Stock or stock options xNone  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or nonxNone	10	in other board, society,	x	
11 Stock or stock options xNone  12 Receipt of equipment,				
12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or nonx_None				
materials, drugs, medical writing, gifts or other services  13 Other financial or nonx_None	11	Stock or stock options	xNone	
materials, drugs, medical writing, gifts or other services  13 Other financial or nonx_None				
materials, drugs, medical writing, gifts or other services  13 Other financial or nonx_None	10			
writing, gifts or other services  13 Other financial or nonx_None	12	materials, drugs, medical writing, gifts or other	xNone	
services  13 Other financial or nonx_None				
13 Other financial or nonx_None				
financial interests	13	Other financial or non-	xNone	

The current study was partially funded by the institutional University Cancer Research Fund via a Lineberger Comprehensive Clinical Cancer Center award.
I am Co-inventor of the stationary digital chest tomosynthesis system.

Please place an "X" next to the following statement to indicate your agreement:				
_x I certify that I have answered every question and have not altered the wording of any of the questions on this form.				